Nkarta, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Nkarta, Inc. (NKTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.86M, a 9.16% decline year-over-year.
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.90M, a 33.03% decline year-over-year.
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.77M, a 56.28% decline year-over-year.
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.05M, a 53.49% decline year-over-year.
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.56M, a 48.84% decline from fiscal 2024.
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $16.73M, a 2.72% decline from fiscal 2023.
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $17.20M, a 2.03% increase from fiscal 2022.
- Nkarta, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $16.86M, a 16.56% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.86M 10-Q · filed 2026-08-10 | $3.76M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $1.90M 10-Q · filed 2026-08-10 | ||||
| 2025-12-31 | $8.56M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $1.77M 10-Q · filed 2025-11-10 | $3.83M derived: sum of 2 quarters · filed 2026-08-10 | $6.66M derived: sum of 3 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $2.05M 10-Q · filed 2026-08-10 | $4.89M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $2.83M 10-Q · filed 2026-08-10 | ||||
| 2024-12-31 | $16.73M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $4.05M 10-Q · filed 2025-11-10 | $8.47M derived: sum of 2 quarters · filed 2025-11-10 | $12.84M derived: sum of 3 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $4.41M 10-Q · filed 2025-11-10 | $8.78M derived: sum of 2 quarters · filed 2025-11-10 | |||
| 2024-03-31 | $4.37M 10-Q · filed 2025-11-10 | ||||
| 2023-12-31 | $17.20M 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | $4.29M 10-Q · filed 2024-11-07 | $8.94M derived: sum of 2 quarters · filed 2024-11-07 | $13.69M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $4.65M 10-Q · filed 2024-11-07 | $9.40M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $4.75M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $16.86M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $4.39M 10-Q · filed 2023-11-09 | $8.30M derived: sum of 2 quarters · filed 2023-11-09 | $12.40M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $3.91M 10-Q · filed 2023-11-09 | $8.01M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $4.10M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $14.46M 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | $3.69M 10-Q · filed 2022-11-09 | $7.38M derived: sum of 2 quarters · filed 2022-11-09 | $10.73M derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $3.69M 10-Q · filed 2022-11-09 | $7.04M derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $3.35M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $6.75M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $1.61M 10-Q · filed 2021-11-10 | $2.17M derived: sum of 2 quarters · filed 2021-11-10 | $2.66M derived: sum of 3 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $566.00K 10-Q · filed 2021-11-10 | $566.09K 10-Q · filed 2020-08-20 | $1.05M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $482.00K 10-Q · filed 2021-11-10 | $482.06K 10-Q · filed 2020-08-20 | |||
| 2019-12-31 | $947.00K 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $227.00K 10-Q · filed 2020-11-12 | $315.00K derived: sum of 2 quarters · filed 2020-11-12 | $382.00K derived: sum of 3 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $88.00K 10-Q · filed 2020-11-12 | $87.57K 10-Q · filed 2020-08-20 | $155.00K derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $67.00K 10-Q · filed 2020-11-12 | $66.88K 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |